Immunosuppressive effect on T cell activation by interleukin- 16-cDNA- transfected human squamous cell line

Cellular Immunology

Volumn 202, Issue 1, 2000, Pages 54-60

  Fujita, Tatsuya ^a   Matsumoto, Yoshitaka ^a   Hirai, Itaru ^a   Ezoe, Kyori ^a   Saito, Tamotsu ^a   Yagihashi, Atsuhito ^a   Torigoe, Toshihiko ^a   Homma, Ken Ichi ^a   Takahashi, Shuji ^a   Cruikshank, William W ^b   Jimbow, Kouichi ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 16;

ALLOGENEIC RESTRICTION; ARTICLE; CANCER CELL CULTURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; SKIN TRANSPLANTATION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION;

EID: 0034713188     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.2000.1657     Document Type: Article

References (23)

1. Brown J. B., Minot P. F., Randall P. Postmortem homograft as "biological dressing" for extensive burns and denuded areas. Ann. Surg. 138:1953;618-629.
2. Zaroff L. I., Mills W., Duckett J. W., Switzer W. E., Moncrief J. A. Multiple uses of viable cutaneous homografts in the burned patient. Surgery. 59:1966;368-372.
3. Spence R. J., Wong L. The enhancement of wound healing with human skin allograft. Surg. Clin. North Am. 77:1977;731-745.
4. Fujita T., Takahashi S., Yagihashi A., Jimbow K., Sato N. Prolonged survival of rat skin allograft by treatment with FK506 ointment. Transplantation. 64:1997;922-925.
5. Krieger N. R., Yin D. P., Fathman C. G. CD4+ but not CD8+ cells are essential for allorejection. J. Exp. Med. 184:1996;2013-2018.
6. Lehman M., Sternkopf F., Metz F., Brock J., Docke W., Plantikow A., Kuttler B., Hahn H., Ringel B., Volk H. Induction of long-term survival of rat skin allograft by a novel, highly efficient anti-CD4 monoclonal antibody. Transplantation. 54:1992;959-962.
7. Theodore A. C., Center D. M., Nicoll J., Fine G., Kornfeld H., Cruikshank W. W. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J. Immunol. 59:1996;1958-1964.
8. Okubo M., Sato N., Wada Y., Takahashi S., Torimoto K., Takahashi N., Sato T., Okazaki M., Asaishi K., Kikuchi K. Identification by monoclonal antibody of the tumor antigen of a human autologous breast cancer cell that is involved in cytotoxicity by a cytotoxic T-cell clone. Cancer Res. 49:1989;3950-3954.
9. Takei T., Ishii Y., Kon S., Fujimoto J., Kikuchi K. Determinant heterogeneity of CD5, CD8 and CD4 antigen molecules as defined by monoclonal antibodies. Leukocyte Typing II. 1986;Springer-Verlag, Berlin.
10. Tamura Y., Tsuboi N., Sato N., Kikuchi K. 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity. J. Immunol. 151:1993;5516-5524.
11. Yamaki T., Uede T., Shijubo N., Kikuchi K. Functional analysis of mononuclear cells infitrating into tumors. III. Soluble factors involved in the regulation of T lymphocyte infiltration into tumors. J. Immunol. 140:1988;4388-4396.
12. Cho J. M., Sato N., Yagihashi A., Hara I., Konnno A., Kon S., Torigoe T., Qi W., Takahashi N., Takashima T., Kikuchi K. Natural killer target molecules associated with the transformation of the oncogene-transformed fibroblast. Cancer Res. 51:1991;4250-4256.
13. Miyazaki A., Sato N., Takahashi S., Sasaki A., Kohama G., Yamaguchi A., Yagihashi A., Kikuchi K. Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma. Jap. J. Cancer Res. 88:1997;191-197.
14. Yokoi T., Hirata S., Nishimura F., Miyakawa A., Odajima T., Kohama G., Mochizuki Y. Some properties of a newly established human cell line derived from a oral squamous carcinoma. Tumor Res. 25:1990;93-103.
15. Morgenstein J. P., Land H. Advanced mammalian gene transfer; High titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:1990;3587-3596.
16. Moritani M., Yoshimoto K., Li S., Kondo M., Iwahara H., Yamaoka T., Sano T., Nakano N., Kukutani H., Itakura M. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. J. Clin. Invest. 98:1996;1851-1859.
17. Peters W. J. Biological dressings in burns - A review. Ann. Plast. Surg. 4:1980;133-137.
18. Alexander J. W., Wheeler L. M., Rooney R. C., Mcdonald J. J., Macmillan B. G. Clinical evaluation of Epigard, a new synthetic substitute for homograft and heterograft skin. J. Trauma. 13:1973;374-383.
19. Friedman S. J., Su W. P. D. Management of leg ulcers with hydrocolloid occlusive dressing. Arch. Dermatol. 120:1984;1329-1336.
20. Albanesi C., Cavani A., Girolomoni G. Interferon-γ stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules. J. Invest. Dermatol. 110:1988;138-142.
21. Cruikshank W. W., Kornfeld H., Center D. M. Signaling and functional properties of interleukin-16. Intern. Rev. Immunol. 16:1988;523-540.
22. Cruickshank W. W., Center D. M., Nisar N., Wu M., Natke B., Theodore A. C., Kornfeld H. Molecular and functional analysis of a lymphocyte chemoattractant factor; Association of biologic function with CD4 expression. Proc. Natl. Acad. Sci. USA. 91:1994;5109-5113.
23. Liu Y., Cruikshank W. W., O'Loughlin T., O'Reilly P., Center D. M., Kornfeld H. Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation. J. Biol. Chem. 274:1999;23387-23395.